See more : Grupo México, S.A.B. de C.V. (GMEXICOB.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Currenc Group, Inc. (CURR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Currenc Group, Inc., a leading company in the Financial – Credit Services industry within the Financial Services sector.
You may be interested
- A1 Group, Inc. (AWON) Income Statement Analysis – Financial Results
- Taurus Armas S.A. (TASA4.SA) Income Statement Analysis – Financial Results
- GCM Securities Limited (GCMSECU.BO) Income Statement Analysis – Financial Results
- Forge Global Holdings, Inc. (FRGE) Income Statement Analysis – Financial Results
- UMC, Inc. (UMCN) Income Statement Analysis – Financial Results
Currenc Group, Inc. (CURR)
Industry: Financial - Credit Services
Sector: Financial Services
Website: https://investors.currencgroup.com/overview/default.aspx
About Currenc Group, Inc.
Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.26M | 4.90M | 6.56M | 2.05M | 623.00K | 583.94K | 180.40K | 84.17K | 183.43K | 251.83K |
| Cost of Revenue | 35.90M | 1.56M | 2.17M | 1.08M | 231.00K | 279.92K | 180.63K | 153.33K | 117.01K | 205.12K |
| Gross Profit | 17.36M | 3.34M | 4.38M | 975.00K | 392.00K | 304.02K | -225.00 | -69.17K | 66.42K | 46.71K |
| Gross Profit Ratio | 32.59% | 68.20% | 66.85% | 47.54% | 62.92% | 52.06% | -0.12% | -82.18% | 36.21% | 18.55% |
| Research & Development | 0.00 | 58.00K | 2.37M | 2.79M | 2.31M | 1.41M | 1.43M | 753.37K | 681.70K | 663.90K |
| General & Administrative | 23.98M | 7.94M | 18.88M | 11.37M | 10.12M | 6.45M | 0.00 | 0.00 | 0.00 | 914.74K |
| Selling & Marketing | 25.88K | 2.23M | 112.89K | 45.12K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.00M | 10.17M | 18.88M | 11.37M | 10.12M | 6.45M | 5.91M | 3.10M | 920.25K | 914.74K |
| Other Expenses | 1.00 | 99.00K | 2.04M | -9.32M | -575.00K | 393.41K | 30.83K | -106.78K | 105.73K | -990.81K |
| Operating Expenses | 24.00M | 11.73M | 21.25M | 14.15M | 12.43M | 7.86M | 7.34M | 3.86M | 1.60M | 587.83K |
| Cost & Expenses | 59.90M | 13.28M | 23.42M | 15.23M | 12.66M | 8.14M | 7.52M | 4.01M | 1.72M | 792.95K |
| Interest Income | 0.00 | 51.00K | 62.00K | 37.00K | 57.00K | 0.00 | 6.00 | 437.00 | 199.00 | 0.00 |
| Interest Expense | 8.00M | 465.00K | 554.00K | 2.47M | 4.11M | 3.04M | 1.58M | 121.57K | 173.46K | -84.84K |
| Depreciation & Amortization | 3.99M | 1.58M | 5.71M | -8.34M | 61.00K | 149.80K | 164.60K | 172.61K | 157.55K | 151.20K |
| EBITDA | -1.90M | -5.54M | 5.39M | -21.52M | -13.46M | -7.28M | -7.15M | -3.86M | -1.27M | -598.48K |
| EBITDA Ratio | -3.57% | -135.99% | -170.21% | -1,049.34% | -1,921.99% | -1,201.23% | -3,961.48% | -4,586.20% | -693.48% | -237.65% |
| Operating Income | -6.65M | -18.27M | -16.87M | -13.18M | -12.04M | -7.56M | -7.34M | -3.93M | -1.54M | -749.68K |
| Operating Income Ratio | -12.48% | -373.16% | -257.32% | -642.56% | -1,931.78% | -1,294.26% | -4,069.81% | -4,664.94% | -837.12% | -297.69% |
| Total Other Income/Expenses | -7.25M | -9.28M | -12.17M | -17.44M | -7.68M | -3.15M | -821.59K | -231.24K | -67.53K | 84.84K |
| Income Before Tax | -13.89M | -6.40M | -13.19M | -30.62M | -21.37M | -10.43M | -8.16M | -4.16M | -1.60M | -664.84K |
| Income Before Tax Ratio | -26.09% | -130.80% | -201.27% | -1,492.98% | -3,430.66% | -1,786.29% | -4,525.23% | -4,939.68% | -873.94% | -264.00% |
| Income Tax Expense | 523.48K | 42.00K | 2.60M | -6.85M | 3.53M | -30.47K | 1.60M | 14.80K | 279.20K | -84.84K |
| Net Income | -15.31M | -6.40M | -15.79M | -23.77M | -24.90M | -10.40M | -8.15M | -4.16M | -1.60M | -580.00K |
| Net Income Ratio | -28.74% | -130.80% | -240.85% | -1,159.14% | -3,996.63% | -1,781.07% | -4,517.57% | -4,939.68% | -873.94% | -230.31% |
| EPS | -0.97 | -0.09 | -0.33 | -0.50 | -0.72 | -0.42 | -0.34 | -0.18 | -0.06 | -0.02 |
| EPS Diluted | -0.33 | -0.09 | -0.33 | -0.50 | -0.72 | -0.42 | -0.34 | -0.18 | -0.06 | -0.02 |
| Weighted Avg Shares Out | 15.86M | 71.41M | 47.19M | 47.31M | 34.54M | 25.00M | 23.65M | 23.33M | 24.98M | 23.27M |
| Weighted Avg Shares Out (Dil) | 46.53M | 71.41M | 47.19M | 47.31M | 34.54M | 25.00M | 23.65M | 23.33M | 24.98M | 23.27M |
CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021. First Quarter 2021 and subsequent weeks...
CURE Pharmaceutical Receives ISO Certification for Laboratory and Manufacturing Facility
LOS ANGELES--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification for its Oxnard, Calif., manufacturing and...
CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin,...
CURE Pharmaceutical's Subsidiary Sera Labs Launches National Television, Radio & Digital Advertising Campaign for Nutri-Strips Sleep A.S.A.P.
LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space today announced that its subsidiary Sera...
CURE Pharmaceutical Announces Promotions and Additions to Board of Directors
OXNARD, Calif.--(BUSINESS WIRE)---- $CURR #CBD--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors. After a...
Sera Labs Unveils ImmunD₃™ an Important New Offering to the Nutri-Strips™ Product Line; Launches New Digital E-commerce Website to Amplify Consumer Awareness
LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)---- $CURR #CBD--According to the National Institute of Health (NIH) more than 50 percent of people worldwide have Vitamin D insufficiency. In response, Sera Labs, Inc., a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB:...
Sera Labs, Inc. Wins Prestigious Retail Excellence Award
LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)---- $CURR #CBD--The retailers have spoken! Sera Labs, Inc., the wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), announced today they have won the coveted Retail Excellence (REX Award) for Natural Products. The Rex...
CURE Pharmaceutical's® Wholly Owned Subsidiary SeraLabs® Introduces Nutri-Strips™, a Revolutionary Oral Thin Film Strip Technology
LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding (OTCQB: CURR) wholly owned subsidiary Sera Labs is challenging the status quo of the health and wellness sector by bringing innovative products to market using groundbreaking technology and superior ingredients. As a...
Source: https://incomestatements.info
Category: Stock Reports